LNDC Landec Corp.

Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences

Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences

CHASKA, Minn., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences and industry events. Details regarding Lifecore’s participation are as follows:

  • TD Cowen 45th Annual Health Care Conference

    Details: Paul Josephs, chief executive officer, will deliver a corporate presentation and Lifecore management will participate in investor meetings

    Presentation Date/Time: Tuesday, March 4, 2025, 9:50 – 10:20 a.m. ET

    Conference Dates: March 3-5, 2025

    Location: Boston, MA
  • KeyBanc Capital Markets Healthcare Forum

    Details: Mr. Josephs will participate in a fireside chat and Lifecore management will participate in investor meetings

    Fireside Chat Date/Time: Wednesday, March 19, 2025, 3:00 – 3:35 p.m. ET

    Conference Dates: March 18-19, 2025

    Location: Virtual
  • DCAT Week 2025

    Details: Lifecore team will participate in meetings with current and prospective customers and attend networking events

    Conference Dates: March 17-20, 2025

    Location: New York, NY

A live webcast of the TD Cowen presentation may be accessed via a link on Lifecore’s investor website on the Investor Events & Presentations page at: . Additionally, a replay of the webcast will be available on the Lifecore website following the conference. 

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: ) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at .



Lifecore Biomedical, Inc. Contact Information:

Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
 

Tim Brons (Media)
415-675-7402
 

Ryan D. Lake (CFO)
Lifecore Biomedical
952-368-6244
 
EN
26/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Landec Corp.

 PRESS RELEASE

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financ...

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update -- Recorded $128.9 Million in Fiscal 2025 Revenue, Meeting Full-Year Guidance; Maintains Commitment to Mid-Term Outlook -- -- Nine New Programs Signed with New Customers During Fiscal 2025, Reflecting Growth into Modalities Beyond the Company's Traditional Area of Strength in Ophthalmic Therapeutics -- -- Improved Efficiency and Productivity Across the Organization -- Conference Call Today at 4:30pm ET CHASKA, Minn., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, In...

 PRESS RELEASE

Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Fina...

Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025 Webcast Scheduled for Thursday, August 7 at 4:30 p.m. Eastern CHASKA, Minn., July 31, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the fourth quarter and fiscal year 2025 on Thursday, August 7, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast ...

 PRESS RELEASE

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...

Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., July 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on July 11, 2025, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate of 6,338 shares of its common stock and stock options for an aggregate of 29,575 shares of common sto...

 PRESS RELEASE

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Sup...

Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer Represents Continuation of Long-Running Partnership Focused on Supporting Advancement of Novel Ophthalmic Therapeutic Toward Commercialization CHASKA, Minn., June 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a new 10-year commercial manufacturing and supply agreement with a key existing customer. This represents the latest agreem...

 PRESS RELEASE

Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Mill...

Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale Fortifies Balance Sheet and Reinforces Disciplined Capital Management Approach CHASKA, Minn., June 12, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has received the remaining $10 million in proceeds from the previously disclosed sale of its excess high-speed, multi-purpose 10-head isolator filler. The buyer elected to complete the full paymen...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch